Scemblix leads the charge in new wave of innovation at Novartis

At the 63rd annual meeting of the American Society of Hematology (ASH), Swiss pharma giant Novartis (NOVN: VX) has announced new positive data for Scemblix (asciminib).

The innovative STAMP blocker is the first approved therapy of its kind, designed to address treatment resistance in chronic myeloid leukemia (CML), and overcome mutations at a defective gene.

Scemblix won US nods at the start of November in two CML indications, including an accelerated approval for adults with Philadelphia chromosome-positive (Ph+) CML as a later-line option. Novartis also secured full approval for adults with Ph+ CML-CP with the T315I mutation.